Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.

Authors:
S Schreiber, S Nikolaus, J Hampe, J Hämling, I Koop, B Groessner, H Lochs, A Raedler
Year of publication:
1999
Volume:
353
Issue:
9151
Issn:
0140-6736
Journal title abbreviated:
LANCET
Journal title long:
Lancet : a journal of British and foreign medicine, surgery ... <et al.> : in two volumes annually
Impact factor:
53.254
Abstract:
Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn''s disease. Experimental immunotherapeutic interventions with anticytokine agents in refractory Crohn''s disease show that tumour necrosis factor alpha (TNF alpha) may be an important mediator of inflammation. We investigated the relation between production of TNF alpha and interleukin 1beta by mononuclear cells of the colonic lamina propria in patients with remitting Crohn''s disease and the risk of relapse.We followed up 137 patients with Crohn''s disease in steroid-induced remission for 1 year. Secretion of proinflammatory cytokines (tumour necrosis factor alpha [TNF alpha] and interleukin 1beta) was assessed after short-term culture of human lamina propria mononuclear cells.Increased secretion of TNF alpha and interleukin 1beta were predictive for acute relapses within the next year. Site and extent of disease, baseline demographics, and serum acute-phase proteins had little predictive value.TNF alpha is important as a target molecule for immune interventions in Crohn''s disease. The capacity to produce TNF alpha or interleukin 1beta may identify patients who would benefit from anti-inflammatory remission maintenance.